Effects of surface modification of As 2 O 3 -loaded PLGA nanoparticles on its anti-liver cancer ability: An in vitro and in vivo study

Song, Xiaoli; You, Juan; Shao, Hongxia; Yan, Caifeng

doi:10.1016/j.colsurfb.2018.05.024

Cited by 24 publications

(18 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nanoparticles based on several different polymers have been proposed as DDSs for ATO. These polymers include polylactic acid (PLA), 53 poly(lactide-co-glycolide) (PLGA), [54][55][56][57]90 sodium alginate, 58 polyamidoamine (PAMAM) dendrimer, 59 pluronic F127 polymer, 91 or chitosan. 92 Polymeric nanoparticles as DDSs of ATO are often prepared by a double emulsion (water-in-oil-in-water = w/o/w) solvent evaporation/extraction method.…”

Section: Polymersmentioning

confidence: 99%

See 1 more Smart Citation

Current status and future prospects of nanomedicine for arsenic trioxide delivery to solid tumors

Sönksen

Kerl

Bunzen

2021

Medicinal Research Reviews

View full text Add to dashboard Cite

Despite having a rich history as a poison, arsenic and its compounds have also gained a great reputation as promising anticancer drugs. As a pioneer, arsenic trioxide has been approved for the treatment of acute promyelocytic leukemia. Many in vitro studies suggested that arsenic trioxide could also be used in the treatment of solid tumors. However, the transition from bench to bedside turned out to be challenging, especially in terms of the drug bioavailability and concentration reaching tumor tissues. To address these issues, nanomedicine tools have been proposed. As nanocarriers of arsenic trioxide, various materials have been examined including liposomes, polymer, and inorganic nanoparticles, and many other materials. This review gives an overview of the existing strategies of delivery of arsenic trioxide in cancer treatment with a focus on the drug encapsulation approaches and medicinal impact in the treatment of solid tumors. It focuses on the progress in the last years and gives an outlook and suggestions for further improvements including theragnostic approaches and targeted delivery.

show abstract

Section: Polymersmentioning

confidence: 99%

“…90 Su et al 54 reported on ATO-loaded PLGA nanoparticles cloaked by red blood cell membrane (RBCM) (Figure 3) to reduce their cytotoxicity as they demonstrated on the human embryonic kidney cell line 293T. Song et al 56 coated PLGA nanoparticles with polyethylene glycol (PEG) and/or lactobionic acid to improve the carrier biocompatibility.…”

Section: Polymersmentioning

confidence: 99%

Current status and future prospects of nanomedicine for arsenic trioxide delivery to solid tumors

Sönksen

Kerl

Bunzen

2021

Medicinal Research Reviews

View full text Add to dashboard Cite

show abstract

“…The surface modification of PLGA NPs with tumor-targeting moieties (i.e., active-targeting strategy) can also enhance anticancer activity [147]. Typical examples can be found in studies using PTX-loaded PLGA NPs, in which the targeting moieties were tethered with the aid of PEG linkers.…”

Section: In Vivo Anticancer Activities Of Plga-based Npsmentioning

confidence: 99%

Recent Progress in the Development of Poly(lactic-co-glycolic acid)-Based Nanostructures for Cancer Imaging and Therapy

et al. 2019

View full text Add to dashboard Cite

Diverse nanosystems for use in cancer imaging and therapy have been designed and their clinical applications have been assessed. Among a variety of materials available to fabricate nanosystems, poly(lactic-co-glycolic acid) (PLGA) has been widely used due to its biocompatibility and biodegradability. In order to provide tumor-targeting and diagnostic properties, PLGA or PLGA nanoparticles (NPs) can be modified with other functional materials. Hydrophobic or hydrophilic therapeutic cargos can be placed in the internal space or adsorbed onto the surface of PLGA NPs. Protocols for the fabrication of PLGA-based NPs for cancer imaging and therapy are already well established. Moreover, the biocompatibility and biodegradability of PLGA may elevate its feasibility for clinical application in injection formulations. Size-controlled NP’s properties and ligand–receptor interactions may provide passive and active tumor-targeting abilities, respectively, after intravenous administration. Additionally, the introduction of several imaging modalities to PLGA-based NPs can enable drug delivery guided by in vivo imaging. Versatile platform technology of PLGA-based NPs can be applied to the delivery of small chemicals, peptides, proteins, and nucleic acids for use in cancer therapy. This review describes recent findings and insights into the development of tumor-targeted PLGA-based NPs for use of cancer imaging and therapy.

show abstract

“…Traditional chemotherapy, with high cytotoxicity in various tissues, is perplexing. Currently, novel nanodrug delivery systems have been studied in order to obtain a better therapy for liver cancer and these systems include polymeric nanoparticles [1, 2], liposomes [3, 4], and inorganic material nanoparticles [5–8]. These forms can improve the drug circulation time in the blood and passively target tumor tissues, due to the enhanced permeability and retention effect (EPR).…”

Section: Introductionmentioning

confidence: 99%

Targeted Delivery of Paclitaxel in Liver Cancer Using Hyaluronic Acid Functionalized Mesoporous Hollow Alumina Nanoparticles

Gao

Liu

et al. 2019

BioMed Research International

View full text Add to dashboard Cite

Hyaluronic acid functionalized mesoporous hollow alumina nanoparticles (HMHA) were used as a tumor-targeted delivery carrier for liver cancer therapy. Paclitaxel (PAC) incorporated in the carrier by the adsorption method was analyzed by X-ray diffraction and differential scanning calorimetry. PAC was found to be in an amorphous state. The hyaluronic acid coated on the surface of mesoporous hollow alumina nanoparticles (MHA) regulated the drug release rate and the loaded samples obtained a sustained drug release. In vitro experiments demonstrated that paclitaxel-hyaluronic acid functionalized mesoporous hollow alumina nanoparticles (PAC-HMHA) had a high cellular uptake, which increased the drug level in tumor tissues and was beneficial to promote apoptosis. An in vivo tumor inhibition rate study demonstrated that PAC-HMHA (64.633 ± 4.389%) had a better antitumor effect than that of paclitaxel-mesoporous alumina nanoparticles (PAC-MHA, 56.019 ± 6.207%) and pure PAC (25.593 ± 4.115%). Therefore it can be concluded that PAC-HMHA are a prospective tumor-targeted delivery medium and can be useful for future cancer therapy.

show abstract

Effects of surface modification of As 2 O 3 -loaded PLGA nanoparticles on its anti-liver cancer ability: An in vitro and in vivo study

Cited by 24 publications

References 36 publications

Current status and future prospects of nanomedicine for arsenic trioxide delivery to solid tumors

Current status and future prospects of nanomedicine for arsenic trioxide delivery to solid tumors

Recent Progress in the Development of Poly(lactic-co-glycolic acid)-Based Nanostructures for Cancer Imaging and Therapy

Targeted Delivery of Paclitaxel in Liver Cancer Using Hyaluronic Acid Functionalized Mesoporous Hollow Alumina Nanoparticles

Contact Info

Product

Resources

About